RS50759B - Formulacije gela 4-hidroksi-tomoksifena - Google Patents

Formulacije gela 4-hidroksi-tomoksifena

Info

Publication number
RS50759B
RS50759B RSP-2009/0248A RSP20090248A RS50759B RS 50759 B RS50759 B RS 50759B RS P20090248 A RSP20090248 A RS P20090248A RS 50759 B RS50759 B RS 50759B
Authority
RS
Serbia
Prior art keywords
gel formulations
hydroxy tamoxifen
tamoxifen gel
hydroxy
tamoxifen
Prior art date
Application number
RSP-2009/0248A
Other languages
English (en)
Inventor
Valérie MASINI-ETEVE
Original Assignee
Laboratoires Besins International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Besins International filed Critical Laboratoires Besins International
Priority claimed from PCT/EP2005/011654 external-priority patent/WO2006040196A1/en
Publication of RS50759B publication Critical patent/RS50759B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmaceutska kompozicija koja sadrži:- 0,205-0,950 % 4-hidroksi-tamoksifena,- 50-75 % najmanje jednog C2-C6 alkohola,- 0,1-5,0 % najmanje jednog sredstva za geliranje,- 0,1-5,0 % najmanje jednog poboljšivača prodiranja,- 20-50 % vodenog prenosnika,pri čemu su procenti (%) težinski u odnosu na ukupnu težinu ove smeše.Prijava sadrži još 13 zavisnih patentnih zahteva.
RSP-2009/0248A 2004-10-14 2005-10-13 Formulacije gela 4-hidroksi-tomoksifena RS50759B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04292447A EP1647271A1 (en) 2004-10-14 2004-10-14 4-Hydroxy tamoxifen gel formulations
US63835904P 2004-12-23 2004-12-23
PCT/EP2005/011654 WO2006040196A1 (en) 2004-10-14 2005-10-13 4-hydroxy tamoxifen gel formulations

Publications (1)

Publication Number Publication Date
RS50759B true RS50759B (sr) 2010-08-31

Family

ID=34931454

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0248A RS50759B (sr) 2004-10-14 2005-10-13 Formulacije gela 4-hidroksi-tomoksifena

Country Status (8)

Country Link
US (2) US20060105041A1 (sr)
EP (1) EP1647271A1 (sr)
KR (1) KR20130049841A (sr)
CN (1) CN101065120B (sr)
NZ (1) NZ554206A (sr)
RS (1) RS50759B (sr)
UA (1) UA87335C2 (sr)
ZA (1) ZA200703016B (sr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ES2263072T3 (es) * 2002-12-18 2006-12-01 Laboratoires Besins International Tratamiento de la mastalgia con 4-hidroxi tamoxifeno.
WO2004054558A2 (en) * 2002-12-18 2004-07-01 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
EP1941871B1 (en) * 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen
NZ544031A (en) * 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
US20070254036A1 (en) * 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
WO2017015125A1 (en) * 2015-07-23 2017-01-26 Anderson S Keith Stratifying breast cancer risk in women with sclerosing adenosis
AU2017312499B2 (en) 2016-08-19 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
CN108210484B (zh) * 2016-12-11 2021-06-25 复旦大学 他莫昔芬凝胶贴膏及其制备方法
WO2023026139A1 (en) * 2021-08-23 2023-03-02 Singh Divya Dhananjay Pharmaceutical composition comprising 4- hydroxytamoxifen for the treatment of mastalgia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US6695171B2 (en) * 2002-02-12 2004-02-24 Seaquistperfect Dispensing Foreign, Inc. Pump dispenser
ES2263072T3 (es) * 2002-12-18 2006-12-01 Laboratoires Besins International Tratamiento de la mastalgia con 4-hidroxi tamoxifeno.
WO2004054558A2 (en) * 2002-12-18 2004-07-01 Laboratoires Besins International Reduction of breast density with 4-hydroxy tamoxifen
EP1941871B1 (en) * 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen
NZ544031A (en) * 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen

Also Published As

Publication number Publication date
NZ554206A (en) 2010-09-30
UA87335C2 (en) 2009-07-10
CN101065120B (zh) 2010-05-05
ZA200703016B (en) 2008-08-27
US20060105041A1 (en) 2006-05-18
EP1647271A1 (en) 2006-04-19
US20170224639A1 (en) 2017-08-10
CN101065120A (zh) 2007-10-31
KR20130049841A (ko) 2013-05-14

Similar Documents

Publication Publication Date Title
RS50759B (sr) Formulacije gela 4-hidroksi-tomoksifena
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BRPI0511466B8 (pt) agonistas peptídicos do receptor de vasopressina, composição farmacêutica compreendendo os referidos agonistas e uso destes
BRPI0500704A (pt) composições de tratamento pessoal reidratáveis
HN2003000417A (es) Intermedio de formulacion aceptablemente no higroscopico que comprende un farmaco higroscopico
BRPI0601896A (pt) composições que contêm microgéis e agentes espessantes
JO2770B1 (en) Organic compounds
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
CR10381A (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
BR112014000178A2 (pt) composições tópicas
GT200900027A (es) Compuestos organicos
BR0311693A (pt) Sal de formato de o-desmetil-venlafaxina
ECSP088109A (es) Composición agrícola
TW200740814A (en) Compounds
CR9786A (es) Compuestos de bencimidazol-tiofeno
CR8617A (es) Formulaciones de dispersiones solidas de acetato de bazedoxifeno
BR122018009866B8 (pt) métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
EA200601279A1 (ru) Пиперидинилкарбонилпирролидины и их применение в качестве агонистов меланокортина
MEP10209A (en) Stable emulsion composition
BRPI0518353A2 (pt) composiÇço imunogÉnica, vÍrus de sÍndrome respiratària e reprodutiva porcina atenuado, e, mÉtodo para proteger um suÍno contra a sÍndrome respiratària e reprodutiva porcina
AR064254A1 (es) Maiz extraido con solvente
CL2004000979A1 (es) Nonapeptidos acilados tipo lysobacitina, composicion que los contiene metodo de preparacion, util como bactericida.
EA200700023A1 (ru) Разрыхляющаяся при пероральном приёме фармацевтическая композиция, содержащая рисперидон
AR053332A1 (es) Uso de agonistas selectivos para el receptor-beta de estrogeno (erp) para la mucositis inducida por radiacion o por quimioterapia y para la cistitis inducida por radiacion
HRP20090239T1 (en) 4-hydroxy tamoxifen gel formulations